Chemical Development (L8)

Introduction

The study of chemical processes in drug development extends beyond chemists, highlighting the collaborative nature of drug synthesis and the importance of understanding chemical principles.

Chemical Synthesis of Small Molecules

Overview of API Synthesis

  • Active Pharmaceutical Ingredients (APIs) are essential components in drug manufacturing.

  • Small molecules are produced via sequential chemical transformations, collectively referred to as the Chemical Route.

  • The synthesis process typically involves 10-15 steps where each step transforms simpler starting materials into complex drug molecules.

  • Transitioning from medicinal chemistry routes to commercial routes is common, as medicinal routes often have more steps and are unsuitable for large-scale production.

Simple Drug Manufacture: Case Study of Aspirin

Acetylation Reaction

  • A straightforward one-step acetylation reaction produces Aspirin from salicylic acid and acetic anhydride.

  • A chemist understands the mechanism, but the essence of the process is adding acetic anhydride to salicylic acid, yielding aspirin and acetic acid.

  • Process chemists are crucial as they determine suitable reactions for large-scale development, addressing potential challenges such as batch size.

Preparing for Scale-Up & Clinical Development

Assess Suitability of Chemistry for Scale

  • Many medicinal chemistry syntheses can be scaled for early clinical phases with modifications.

  • Key areas to evaluate include:

    • Hazardous Reactions: Require modification if they pose safety risks.

    • Specialised Reactions: Such as those needing extreme conditions.

    • Manual Workups: These should be minimized to ensure scalability.

    • Impurity Management: Critical for ensuring drug safety and efficacy.

    • Outsourcing: Robust plans are essential when contracting research organizations for scale-ups.

Synthesis of Sildenafil Citrate (Viagra)

Discovery and Process Overview

  • Minor modifications allow the linear synthesis of sildenafil citrate to transition smoothly into Phase I material for clinical trials.

  • Environmental impacts must be considered, particularly regarding waste generated during reactions.

Control of Impurities

Guidelines

  • Impurities, defined as any component of a new drug substance not aligned with the chemical identity, must be meticulously controlled for human-use drugs.

  • Regulatory guidelines exist for checking these impurities to ensure safety and compliance during development.

ICH Q3A Impurity Thresholds

  • Impurities not classified as unusually toxic do not need to adhere strictly to thresholds in early development.

  • However, excessive impurities (above 0.5%) can hinder clinical progression.

  • Qualification of impurities includes gathering data on biological safety and proving a drug's safety at specified impurity levels, which often takes years and considerable resources.

Mutagenic Impurities

Definition and Control

  • Mutagenic impurities can cause DNA mutations and must be rigorously controlled during preclinical phases to prevent false results in assays and clinical holds.

  • The chemistry process must be scrutinized for potential mutagenic impurity formation, especially during the drug development workflow.

Salts in Drug Development

Considerations and Definitions

  • Salts, resulting from acid-base neutralization, alter the physical properties of APIs.

  • Regulatory approval is often limited to specific counterions, enhancing solubility, stability, and pharmacological properties of the drug.

Polymorphism

Understanding Polymorphs

  • Polymorphism involves solid materials existing in different crystalline forms, each with distinct properties.

  • Selection is typically based on thermodynamic stability to ensure effective drug action.

  • Screening methods often test drugs in various solvents to identify optimal crystalline forms for development.

Quality Standards in Drug Manufacturing

Distinction between Pre-Clinical and Clinical Standards

  • Clinical APIs must adhere to stringent Good Manufacturing Practices (GMP) outlined in ICH Q7.

  • Non-Clinical APIs follow less stringent General Laboratory Practices (GLP), with standards influenced more by business risk than defined quality measures.

Pre-Clinical Stability Studies

Importance and Process

  • Stability studies are crucial for understanding an API's durability during trials.

  • Methods include exposing substances to physiological conditions and analyzing degradation products using chemical assays.

Regulatory Considerations for Phase 1 Trials

Necessary Documentation

  • Precise regulations streamline transitions to clinical phases, demanding comprehensive documentation such as the Investigator's Brochure (IB) and Investigational New Drug (IND) applications.

Conclusion

The synthesis, control, and regulatory aspects of drug development encompass a diverse range of chemical processes and principles. Understanding these facets is imperative for successful pharmaceutical development and commercialization.